Resmed (RMD) Net Equity Issued and Repurchased (2009 - 2026)

Resmed's Net Equity Issued and Repurchased history runs 18 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 17.69% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.3 million (up 4.68% YoY) and the FY2025 annual result came in at $74.4 million, up 40.2% from the prior year.
• Net Equity Issued and Repurchased was $7.4 million for Q1 2026 at Resmed, down from $29.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $30.2 million in Q2 2025 and bottomed at $983000.0 in Q1 2023.
• A 5-year average of $14.5 million and a median of $9.0 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased surged 1840.69% — and 2023, when it tumbled 65.07%.
• Resmed's Net Equity Issued and Repurchased stood at $22.1 million in 2022, then retreated by 11.48% to $19.5 million in 2023, then jumped by 37.66% to $26.9 million in 2024, then rose by 9.97% to $29.6 million in 2025, then sank by 74.87% to $7.4 million in 2026.
• Business Quant data shows RMD's Net Equity Issued and Repurchased at $7.4 million in Q1 2026, $29.6 million in Q4 2025, and $8.2 million in Q3 2025.